BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Israel approves 19 new West Bank settlements in major annexation push - 2Bomb blast in packed Nigerian mosque kills five
- 3Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- 4U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- 5Experience Arranging: Planning for Epic Excursions
- Vote in favor of your Number one natural product
- The Ascent of Robots: Occupations That Man-made brainpower Might Dispense with
- The Main 15 Powerful Business Heads of Today
- RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- Vote in favor of your Number one method for commending a birthday
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- Moving Pool Highlights for 2024
- ‘RichTok’ Influencer Becca Bloom Shows Off Custom Invitations and ‘Most Valued Possession’ from Her Viral 2025 Wedding
- 'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia
